{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:12:26Z","timestamp":1769159546997,"version":"3.49.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["602295"],"award-info":[{"award-number":["602295"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.drudis.2020.08.005","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T11:18:47Z","timestamp":1598008727000},"page":"1957-1970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacology of enalapril in children: a review"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-2459","authenticated-orcid":false,"given":"Nori J.L.","family":"Smeets","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9725-4856","authenticated-orcid":false,"given":"Michiel F.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel","family":"Dalinghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Male","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian B.","family":"Lagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Laer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-0647","authenticated-orcid":false,"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2020.08.005_bib0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2125.1981.tb01151.x","article-title":"Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects","volume":"11","author":"Brunner","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11906-012-0316-1","article-title":"Direct activation of ENaC by angiotensin II: recent advances and new insights","volume":"15","author":"Zaika","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.drudis.2020.08.005_bib0015","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1161\/01.CIR.88.5.2277","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators","volume":"88","author":"Konstam","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11906-017-0771-9","article-title":"Effects of RAAS inhibitors in patients with kidney disease","volume":"19","author":"Zhang","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.drudis.2020.08.005_bib0025","series-title":"Committee for Proprietary Medicinal Products (CPMP) Summary Information of Referral Opinion Pursuant to Article 30 of Council Directive 2001\/83\/EC for Renitec and Associated Names","author":"The European Agency for the Evaluation of Medicinal Products","year":"2003"},{"key":"10.1016\/j.drudis.2020.08.005_bib0030","doi-asserted-by":"crossref","first-page":"e000365","DOI":"10.1136\/bmjpo-2018-000365","article-title":"Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey","volume":"3","author":"Castro Diez","year":"2019","journal-title":"BMJ Paediatr. Open."},{"key":"10.1016\/j.drudis.2020.08.005_bib0035","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.healun.2015.01.980","article-title":"Management of children with dilated cardiomyopathy in The Netherlands: Implications of a low early transplantation rate","volume":"34","author":"den Boer","year":"2015","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.drudis.2020.08.005_bib0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00003088-198510050-00001","article-title":"Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review","volume":"10","author":"Kubo","year":"1985","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.drudis.2020.08.005_bib0045","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1023\/A:1015885823793","article-title":"Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery","volume":"9","author":"Bai","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2020.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1023\/A:1016071027177","article-title":"Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies","volume":"13","author":"Morrison","year":"1996","journal-title":"Pharm. Res"},{"key":"10.1016\/j.drudis.2020.08.005_bib0055","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1124\/jpet.108.143339","article-title":"Transport of angiotensin-converting enzyme inhibitors by H+\/peptide transporters revisited","volume":"327","author":"Knutter","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2020.08.005_bib0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2125.1982.tb01992.x","article-title":"Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system","volume":"14","author":"Biollaz","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2125.1982.tb01991.x","article-title":"Enalapril maleate and a lysine analogue (MK-521): disposition in man","volume":"14","author":"Ulm","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0070","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2005.00646.x","article-title":"Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays","volume":"30","author":"Arafat","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.drudis.2020.08.005_bib0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1472-8206.2002.00087.x","article-title":"Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis","volume":"16","author":"Matalka","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/bmc.1716","article-title":"Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry","volume":"26","author":"Ramusovic","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/03602538308991383","article-title":"Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man","volume":"14","author":"Ulm","year":"1983","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.drudis.2020.08.005_bib0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/jpet.106.103390","article-title":"Vectorial transport of enalapril by Oatp1a1\/Mrp2 and OATP1B1 and OATP1B3\/MRP2 in rat and human livers","volume":"318","author":"Liu","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2020.08.005_bib0095","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1124\/dmd.114.057554","article-title":"Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat","volume":"42","author":"Ferslew","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2020.08.005_bib0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.tpj.6500451","article-title":"Variability in human hepatic MRP4 expression: influence of cholestasis and genotype","volume":"8","author":"Gradhand","year":"2008","journal-title":"Pharmacogenomics J."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2020.08.005_bib0105","first-page":"215s","article-title":"An overview of the clinical pharmacology of enalapril","volume":"18","author":"Davies","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-6147(00)01994-5","article-title":"The angiotensin-converting enzyme gene family: genomics and pharmacology","volume":"23","author":"Turner","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drudis.2020.08.005_bib0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2165\/00003088-199325040-00003","article-title":"Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview","volume":"25","author":"MacFadyen","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drudis.2020.08.005_bib0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0272-6386(12)70119-1","article-title":"Renal handling of enalaprilat","volume":"19","author":"Mujais","year":"1992","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.drudis.2020.08.005_bib0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF02353517","article-title":"Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations","volume":"24","author":"Kugler","year":"1996","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.drudis.2020.08.005_bib0130","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3389\/fphar.2020.00802","article-title":"Identification of structural features for the inhibition of OAT3-mediated uptake of enalaprilat by selected drugs and flavonoids","volume":"11","author":"Ni","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00005344-198811000-00003","article-title":"Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers","volume":"12","author":"Ishizaki","year":"1988","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/bdd.2510050309","article-title":"Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers","volume":"5","author":"Till","year":"1984","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.drudis.2020.08.005_bib0145","series-title":"Nelson Textbook of Pediatrics (Ch. 57, 18th edn.)","first-page":"335","article-title":"Principles of drug therapy","author":"Kliegman","year":"2007"},{"key":"10.1016\/j.drudis.2020.08.005_bib0150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2165\/00003495-199243030-00005","article-title":"Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension","volume":"43","author":"Todd","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2020.08.005_bib0155","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2125.1987.tb03069.x","article-title":"The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure","volume":"23","author":"Dickstein","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00005344-198507000-00023","article-title":"Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension","volume":"7","author":"Schwartz","year":"1985","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0165","unstructured":"Summary Of Product Characteristics (SPC, SmPC), Enalapril maleate tablets 30mg. 2010, https:\/\/db.cbg-meb.nl\/mri\/spc\/nlh-0517-001-002.pdf"},{"key":"10.1016\/j.drudis.2020.08.005_bib0170","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/jps.2600731146","article-title":"Influence of food on the bioavailability of enalapril","volume":"73","author":"Swanson","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2020.08.005_bib0175","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cpdd.129","article-title":"Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets","volume":"3","author":"Moffett","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.drudis.2020.08.005_bib0180","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.118.080523","article-title":"Abundance of Phase 1 and 2 drug-metabolizing enzymes in alcoholic and hepatitis C cirrhotic livers: a quantitative targeted proteomics study","volume":"46","author":"Prasad","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2020.08.005_bib0185","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ki.2013.399","article-title":"Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport","volume":"85","author":"Yeung","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2020.08.005_bib0190","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcp.2008.10.005","article-title":"Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin","volume":"77","author":"Yang","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2125.1986.tb02823.x","article-title":"Pharmacokinetics of enalapril in normal subjects and patients with renal impairment","volume":"21","author":"Kelly","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0200","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1177\/00912700122012661","article-title":"The pharmacokinetics of enalapril in children and infants with hypertension","volume":"41","author":"Wells","year":"2001","journal-title":"J. Clin. Pharmacol"},{"key":"10.1016\/j.drudis.2020.08.005_bib0205","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/clpt.1994.119","article-title":"The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure","volume":"56","author":"Nakamura","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2020.08.005_bib0210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3476(89)80715-2","article-title":"Orally administered enalapril for infants with congestive heart failure: a dose-finding study","volume":"114","author":"Lloyd","year":"1989","journal-title":"J. Pediatr"},{"issue":"4","key":"10.1016\/j.drudis.2020.08.005_bib0215","first-page":"43","article-title":"Radioimmunoassay for angiotensin converting enzyme inhibitors","volume":"1984","author":"Hichens","year":"1984","journal-title":"Ligand Q."},{"key":"10.1016\/j.drudis.2020.08.005_bib0220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/dmd.116.072652","article-title":"Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS\/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants","volume":"45","author":"Boberg","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2020.08.005_bib0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","article-title":"Ontogeny of drug elimination by the human kidney","volume":"21","author":"Chen","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lfs.2016.11.022","article-title":"Ontogeny, aging, and gender-related changes in hepatic multidrug resistant protein genes in rats","volume":"170","author":"Zhu","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2020.08.005_bib0235","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/00005344-198309000-00005","article-title":"Humoral and renal effects of MK-421 (enalapril) in hypertensive subjects","volume":"5","author":"de Leeuw","year":"1983","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0240","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.CIR.63.3.645","article-title":"Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure","volume":"63","author":"Dzau","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0245","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0250","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF00442742","article-title":"The renin-angiotensin-aldosterone system in infancy and childhood in basal conditions and after stimulation","volume":"143","author":"Fiselier","year":"1984","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0255","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2125.1993.tb04180.x","article-title":"Inhibition of angiotensin converting enzyme with enalapril maleate in infants with congestive heart failure","volume":"35","author":"Dutertre","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S1047951100000524","article-title":"Effect of enalapril on infants and children with congestive heart failure","volume":"2","author":"Seguchi","year":"1992","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.drudis.2020.08.005_bib0265","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.118.10862","article-title":"Pharmacological treatment of arterial hypertension in children and adolescents: a network meta-analysis","volume":"72","author":"Burrello","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2020.08.005_bib0270","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/009127002401102786","article-title":"A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension","volume":"42","author":"Wells","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0275","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1097\/HJH.0b013e32834c625c","article-title":"Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study","volume":"29","author":"Schaefer","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.drudis.2020.08.005_bib0280","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/jhh.2015.87","article-title":"Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation","volume":"30","author":"Di Salvo","year":"2016","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.drudis.2020.08.005_bib0285","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1651-2227.1995.tb13581.x","article-title":"Use of enalapril in neonatal hypertension","volume":"84","author":"Schilder","year":"1995","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0290","doi-asserted-by":"crossref","DOI":"10.1055\/s-2007-994783","article-title":"Treatment of neonatal renovascular hypertension with intravenous enalapril","volume":"9","author":"Mason","year":"1992","journal-title":"Am. J. Perinatol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0295","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-3476(05)82082-7","article-title":"Use of enalaprilat for neonatal hypertension","volume":"119","author":"Marcadis","year":"1991","journal-title":"J. Pediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0300","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0022-3476(05)80711-5","article-title":"Treatment of neonatal hypertension with enalaprilat","volume":"117","author":"Wells","year":"1990","journal-title":"J. Pediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0305","first-page":"S413","article-title":"Enalapril: a well-tolerated and efficacious agent for the paediatric hypertensive patient","volume":"4","author":"Miller","year":"1986","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.drudis.2020.08.005_bib0310","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/jphp.12471","article-title":"Extrapolation of enalapril efficacy from adults to children using pharmacokinetic\/pharmacodynamic modelling","volume":"67","author":"Kechagia","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0315","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.31.5.1088","article-title":"Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives","volume":"31","author":"Weir","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2020.08.005_bib0320","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/clpt.2008.113","article-title":"Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis","volume":"84","author":"Li","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2020.08.005_bib0325","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2169\/internalmedicine1962.24.44","article-title":"A case of hyperreninemic hypertension with unilateral hydronephrosis","volume":"24","author":"Urata","year":"1985","journal-title":"Jpn. J. Med."},{"key":"10.1016\/j.drudis.2020.08.005_bib0330","first-page":"217","article-title":"Response of malignant hypertension with refractory cardiac failure to captopril: a case report","volume":"58","author":"Levin","year":"1980","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.drudis.2020.08.005_bib0335","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0735-1097(00)00673-2","article-title":"Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study","volume":"36","author":"Mori","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0340","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1161\/CIRCULATIONAHA.104.528695","article-title":"Angiotensin-converting enzyme inhibitors: a new mechanism of action","volume":"112","author":"Peng","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0345","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0350","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.drudis.2020.08.005_bib0355","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCULATIONAHA.109.927988","article-title":"Enalapril in infants with single ventricle: results of a multicenter randomized trial","volume":"122","author":"Hsu","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0360","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/adc.70.1.35","article-title":"Efficacy and dosage of enalapril in congenital and acquired heart disease","volume":"70","author":"Leversha","year":"1994","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.drudis.2020.08.005_bib0365","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00793943","article-title":"Acute hemodynamic effects of converting enzyme inhibition in children with intracardiac shunts","volume":"13","author":"Webster","year":"1992","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0370","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0002-9149(92)90749-O","article-title":"Intravenous enalaprilat and oral enalapril in congestive heart failure secondary to ventricular septal defect in infancy","volume":"70","author":"Sluysmans","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0375","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0022-3476(05)80712-7","article-title":"Acute hemodynamic effects of converting enzyme inhibition in infants with congestive heart failure","volume":"117","author":"Rheuban","year":"1990","journal-title":"J. Pediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00794837","article-title":"The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy","volume":"14","author":"Lewis","year":"1993","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0385","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00246-002-0046-2","article-title":"Afterload reduction therapy in patients following intraatrial baffle operation for transposition of the great arteries","volume":"23","author":"Robinson","year":"2002","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0390","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1651-2227.1991.tb11905.x","article-title":"Enalapril in children with congestive heart failure","volume":"80","author":"Eronen","year":"1991","journal-title":"Acta Paediatr. Scand."},{"key":"10.1016\/j.drudis.2020.08.005_bib0395","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","article-title":"Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0400","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/adc.64.2.219","article-title":"Enalapril for severe heart failure in infancy","volume":"64","author":"Frenneaux","year":"1989","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.drudis.2020.08.005_bib0405","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1161\/01.CIR.96.5.1507","article-title":"Enalapril does not enhance exercise capacity in patients after Fontan procedure","volume":"96","author":"Kouatli","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0410","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1017\/S104795111600295X","article-title":"Translating clinical trials into clinical practice: a survey assessing the potential impact of the Pediatric Heart Network Infant Single Ventricle Trial","volume":"27","author":"Zak","year":"2017","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.drudis.2020.08.005_bib0415","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1161\/CIRCULATIONAHA.110.986315","article-title":"Letter by Burchill et al. regarding article, \"Enalapril in infants with single ventricle: results of a multicenter randomized trial","volume":"123","author":"Burchill","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0420","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1161\/CIRCULATIONAHA.110.989897","article-title":"Letter by Singh regarding article, \"Enalapril in infants with single ventricle: results of a multicenter randomized trial","volume":"123","author":"Singh","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0425","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1681\/ASN.2018010036","article-title":"Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD","volume":"29","author":"van den Belt","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0430","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2215\/CJN.01780408","article-title":"Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study","volume":"4","author":"Wong","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0435","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00467-012-2372-9","article-title":"Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome","volume":"28","author":"Webb","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0440","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ki.2012.210","article-title":"Losartan and enalapril are comparable in reducing proteinuria in children","volume":"82","author":"Webb","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2020.08.005_bib0445","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00467-011-1867-0","article-title":"Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy","volume":"26","author":"Caletti","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0450","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00467-003-1314-y","article-title":"Enalapril dosage in steroid-resistant nephrotic syndrome","volume":"19","author":"Bagga","year":"2004","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0455","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s13312-013-0262-2","article-title":"Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial","volume":"50","author":"Hari","year":"2013","journal-title":"Indian Pediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0460","first-page":"476","article-title":"Enalapril treatment of proteinuria in normotensive children","volume":"100","author":"Sasinka","year":"1999","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.drudis.2020.08.005_bib0465","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s004310051301","article-title":"Enalapril in paediatric patients with Alport syndrome: 2 years\u2019 experience","volume":"159","author":"Proesmans","year":"2000","journal-title":"Eur. J. Pediatr"},{"key":"10.1016\/j.drudis.2020.08.005_bib0470","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s004670050166","article-title":"Long-term therapy with enalapril in patients with nephrotic-range proteinuria","volume":"10","author":"Proesmans","year":"1996","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0475","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s004670050420","article-title":"Adequate clinical control of congenital nephrotic syndrome by enalapril","volume":"12","author":"Guez","year":"1998","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0480","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-3476(88)80073-8","article-title":"Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease","volume":"112","author":"Trachtman","year":"1988","journal-title":"J. Pediatr"},{"key":"10.1016\/j.drudis.2020.08.005_bib0485","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00467-012-2374-7","article-title":"Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome","volume":"28","author":"Caletti","year":"2013","journal-title":"Pediatr. Nephrol"},{"key":"10.1016\/j.drudis.2020.08.005_bib0490","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.20296","article-title":"Enalapril and hydroxyurea therapy for children with sickle nephropathy","volume":"45","author":"Fitzhugh","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.drudis.2020.08.005_bib0495","first-page":"432","article-title":"Enalapril: antiproteinuric effect in children with nephrotic syndrome","volume":"53","author":"Lama","year":"2000","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0500","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003495-198631030-00002","article-title":"Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure","volume":"31","author":"Todd","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2020.08.005_bib0505","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000441950","article-title":"Enalapril associated with furosemide induced acute kidney injury in an infant with heart failure. A case report, a revision of the literature and a pharmacovigilance database analysis","volume":"97","author":"Fabiano","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.drudis.2020.08.005_bib0510","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cpt.1018","article-title":"Rate of cough during treatment with angiotensin-converting enzyme inhibitors: a meta-analysis of randomized placebo-controlled trials","volume":"105","author":"Vukadinovic","year":"2019","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.drudis.2020.08.005_bib0515","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/jch.13097","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature","volume":"19","author":"Brown","year":"2017","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.drudis.2020.08.005_bib0520","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/archdischild-2017-312774","article-title":"Question 1: How safe are ACE inhibitors for heart failure in children?","volume":"103","author":"van der Meulen","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.drudis.2020.08.005_bib0525","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bdra.20102","article-title":"Angiotensin II receptor antagonist treatment during pregnancy","volume":"73","author":"Alwan","year":"2005","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0530","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/pds.796","article-title":"Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment","volume":"12","author":"Tabacova","year":"2003","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drudis.2020.08.005_bib0535","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00006565-200112000-00009","article-title":"Angiotensin-converting enzyme inhibitor angioedema in a pediatric patient: a case report and discussion","volume":"17","author":"Quintana","year":"2001","journal-title":"Pediatr. Emerg. Care"},{"key":"10.1016\/j.drudis.2020.08.005_bib0540","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000045552","article-title":"Cough is common in children prescribed converting enzyme inhibitors","volume":"84","author":"von Vigier","year":"2000","journal-title":"Nephron"},{"key":"10.1016\/j.drudis.2020.08.005_bib0545","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0550","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jcph.13","article-title":"Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature","volume":"53","author":"Salem","year":"2013","journal-title":"J. Clin. Pharmacol"},{"key":"10.1016\/j.drudis.2020.08.005_bib0555","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40620-013-0009-0","article-title":"Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension","volume":"27","author":"Assadi","year":"2014","journal-title":"J. Nephrol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0560","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1542\/hpeds.2017-0124","article-title":"An investigation of drug-drug interaction alert overrides at a pediatric hospital","volume":"8","author":"Humphrey","year":"2018","journal-title":"Hosp. Pediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0565","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s12098-009-0180-4","article-title":"Complications during enalapril and diuretic therapy for congestive cardiac failure","volume":"76","author":"Mehta","year":"2009","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.drudis.2020.08.005_bib0570","series-title":"Evidence of Harm from Off-Label or Unlicensed Medicines in Children","author":"European Medicines Agency","year":"2004"},{"key":"10.1016\/j.drudis.2020.08.005_bib0575","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2018.02.037","article-title":"Flexible and precise dosing of enalapril maleate for all paediatric age groups utilizing orodispersible minitablets","volume":"541","author":"Thabet","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2020.08.005_bib0580","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/cpdd.728","article-title":"Relative bioavailability of enalapril administered as orodispersible minitablets in healthy adults","volume":"9","author":"Van Hecken","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.drudis.2020.08.005_bib0585","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2147\/DDDT.S188417","article-title":"Model-dependent pharmacokinetic analysis of enalapril administered to healthy adult volunteers using orodispersible minitablets for use in pediatrics","volume":"13","author":"Faisal","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.drudis.2020.08.005_bib0590","doi-asserted-by":"crossref","first-page":"100393","DOI":"10.1016\/j.conctc.2019.100393","article-title":"Orodispersible minitablets of enalapril for use in children with heart failure (LENA): rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study","volume":"15","author":"Bajcetic","year":"2019","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.drudis.2020.08.005_bib0595","unstructured":"Enalaprilat: Tox and Drug Product results (2020). In Micromedex (Radboud University Medical Center) [Electronic version]. Retrieved August 24, 2020, from http:\/\/www.micromedexsolutions.com\/"},{"key":"10.1016\/j.drudis.2020.08.005_bib0600","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/CIRCULATIONAHA.113.003615","article-title":"Update on pharmacological heart failure therapies in children: do adult medications work in children and if not, why not?","volume":"129","author":"Rossano","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0605","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10557-017-6733-2","article-title":"The pharmacogenomic and metabolomic predictors of ace inhibitor and angiotensin ii receptor blocker effectiveness and safety","volume":"31","author":"Flaten","year":"2017","journal-title":"Cardiovasc. Drugs Ther"},{"key":"10.1016\/j.drudis.2020.08.005_bib0610","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bcpt.12835","article-title":"The pharmacokinetics of enalapril in relation to CES1 genotype in healthy Danish volunteers","volume":"121","author":"Stage","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0615","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/bcp.13237","article-title":"The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects","volume":"83","author":"Stage","year":"2017","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1016\/j.drudis.2020.08.005_bib0620","doi-asserted-by":"crossref","DOI":"10.2217\/pme.13.70","article-title":"Pharmacogenetics in clinical pediatrics: challenges and strategies","author":"Van Driest","year":"2013","journal-title":"Per. Med."},{"key":"10.1016\/j.drudis.2020.08.005_bib0625","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.110.004341","article-title":"Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle","volume":"123","author":"Mital","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2020.08.005_bib0630","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jamacardio.2017.1239","article-title":"Sildenafil treatment in heart failure with preserved ejection fraction: targeted metabolomic profiling in the RELAX Trial","volume":"2","author":"Wang","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.drudis.2020.08.005_bib0635","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1161\/HYPERTENSIONAHA.117.09819","article-title":"Citric acid metabolism in resistant hypertension: underlying mechanisms and metabolic prediction of treatment response","volume":"70","author":"Martin-Lorenzo","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2020.08.005_bib0640","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1253\/circj.CJ-17-1184","article-title":"Metabolomic analysis in heart failure","volume":"82","author":"Ikegami","year":"2017","journal-title":"Circ. J."},{"key":"10.1016\/j.drudis.2020.08.005_bib0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153163","article-title":"The pharmacogenetic footprint of ACE inhibition: a population-based metabolomics study","volume":"11","author":"Altmaier","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2020.08.005_bib0650","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/CS20160414","article-title":"Perspective on precision medicine in paediatric heart failure","volume":"131","author":"Fridman","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.drudis.2020.08.005_bib0655","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clinbiochem.2013.11.018","article-title":"Clinical metabolomics and hematic ADMA predict the future onset of cardiorenal syndrome in young grown-up subjects who were born preterm","volume":"47","author":"Bassareo","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.drudis.2020.08.005_bib0660","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1021\/acs.jproteome.5b00699","article-title":"Metabolomics study of urine in autism spectrum disorders using a multiplatform analytical methodology","volume":"14","author":"Dieme","year":"2015","journal-title":"J. Proteome Res"},{"key":"10.1016\/j.drudis.2020.08.005_bib0665","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13229-016-0109-5","article-title":"Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism","volume":"7","author":"Gevi","year":"2016","journal-title":"Mol. Autism"},{"key":"10.1016\/j.drudis.2020.08.005_bib0670","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/ped.13063","article-title":"Is there a role for stool metabolomics in cystic fibrosis?","volume":"58","author":"Kaakoush","year":"2016","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.drudis.2020.08.005_bib0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183185","article-title":"Metabolomics reveals an entanglement of fasting leptin concentrations with fatty acid oxidation and gluconeogenesis in healthy children","volume":"12","author":"Kirchberg","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2020.08.005_bib0680","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/pr.2016.72","article-title":"Metabolites involved in glycolysis and amino acid metabolism are altered in short children born small for gestational age","volume":"80","author":"Murray","year":"2016","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.drudis.2020.08.005_bib0685","doi-asserted-by":"crossref","first-page":"e1240","DOI":"10.1038\/tp.2017.211","article-title":"Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort","volume":"7","author":"O\u2019Gorman","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.drudis.2020.08.005_bib0690","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/oby.21926","article-title":"Metabolomic determinants of metabolic risk in Mexican adolescents","volume":"25","author":"Perng","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.drudis.2020.08.005_bib0695","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/cea.13183","article-title":"Plasma metabolite profiles in children with current asthma","volume":"48","author":"Kelly","year":"2018","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.drudis.2020.08.005_bib0700","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/nu9050485","article-title":"Urinary metabolomics in pediatric obesity and NAFLD identifies metabolic pathways\/metabolites related to dietary habits and gut-liver axis perturbations","volume":"9","author":"Troisi","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.drudis.2020.08.005_bib0705","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/nbm.1395","article-title":"1H NMR metabolomics study of age profiling in children","volume":"22","author":"Gu","year":"2009","journal-title":"NMR Biomed."},{"key":"10.1016\/j.drudis.2020.08.005_bib0710","first-page":"1346026","article-title":"Guidelines for reporting medical research: a critical appraisal","volume":"2016","author":"Johansen","year":"2016","journal-title":"Int. Sch. Res. Notices"},{"key":"10.1016\/j.drudis.2020.08.005_bib0715","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ahj.2010.10.030","article-title":"Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study","volume":"161","author":"Li","year":"2011","journal-title":"Am. Heart J."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620303366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620303366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:47:42Z","timestamp":1761223662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620303366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":143,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1359644620303366"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.08.005","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology of enalapril in children: a review","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}